Pharmaceutical Excipients: The Complete Manufacturing Guide

AMBICEL MCC 101 is Maple Biotech's standard-grade Microcrystalline Cellulose with a nominal particle size of 50 µm, manufactured from alpha-cellulose pulp by partial depolymerisation with dilute mineral acid followed by spray drying. The resulting free-flowing, white powder is chemically identical to PH-101 as defined in the USP/NF, European Pharmacopoeia, Indian Pharmacopoeia, and Japanese Pharmacopoeia monographs for Microcrystalline Cellulose.

MCC 101 is the most versatile MCC grade, suitable for both wet granulation — where it contributes binding strength and dilution — and direct compression at moderate concentrations. Its crystalline structure provides exceptional compressibility: tablets formed with MCC 101 exhibit high hardness at low compression forces, reducing tooling wear and punch-face sticking. The material is chemically inert, non-toxic, and compatible with the vast majority of API chemistries including acidic, basic, and oxidation-sensitive molecules.

Key quality attributes include loss on drying ≤ 5.0%, pH 5.0–7.5, bulk density 0.28–0.34 g/cm³, and heavy metals <10 ppm (ICH Q3D compliant). Shelf life is 5 years from date of manufacture in sealed original packaging at ≤25°C / ≤65% RH. Every batch ships with a full pharmacopoeial CoA and WHO-GMP batch record.

AMBICEL MCC 102 is the high-flow direct compression grade of Microcrystalline Cellulose, with a nominal particle size of 90 µm — twice that of MCC 101. The larger particle size results in significantly better powder flowability (Carr index typically 20–25) and higher bulk density compared to PH-101, making AMBICEL MCC 102 the preferred choice for high-speed rotary tablet presses where consistent die filling is paramount.

The direct compression performance of AMBICEL MCC 102 is superior to MCC 101: it forms harder tablets at equivalent compression forces and exhibits excellent self-disintegrating behaviour due to its crystalline capillary structure which rapidly wicks water into the tablet matrix. This dual binder-disintegrant functionality allows formulators to reduce the total excipient load, particularly valuable in high-dose formulations where API space in the tablet is at a premium.

AMBICEL MCC 102 meets USP/NF <776>, EP 2.9.12, IP, and JP specifications concurrently. Key attributes: LOD ≤5.0%, bulk density 0.28–0.38 g/cm³, pH 5.0–7.5, degree of polymerisation ≥200, and residual heavy metals compliant with ICH Q3D. Shelf life: 5 years sealed at ≤25°C. CoA and DMF LOA support available for all registered customers.

AMBICEL MCC 112 is Silicified Microcrystalline Cellulose (SMCC) — a co-processed composite of MCC PH-102 (90 µm) intimately blended with approximately 2% colloidal silicon dioxide during the spray-drying step. The silicification process creates a permanent, homogeneous coating of silicon dioxide on the MCC particle surface, fundamentally improving powder characteristics without altering the chemical identity of either component.

Compared to conventional MCC 102, AMBICEL MCC 112 offers measurably better powder flowability (lower Carr index, higher Hausner ratio improvement), superior moisture resistance due to the hydrophobic silica surface layer, and enhanced lubrication efficiency — meaning lower concentrations of magnesium stearate are required. These properties make SMCC particularly valuable for moisture-sensitive APIs and formulations where over-lubrication with magnesium stearate is a dissolution concern.

AMBICEL MCC 112 complies with USP/NF monographs for Silicified Microcrystalline Cellulose, EP monograph for Microcrystalline Cellulose and Carmellose Sodium, and IP. Typical compressibility index: ≤18. LOD ≤5.0%. SiO₂ content 1.5–3.0%. ICH Q3D compliant for elemental impurities. Shelf life: 5 years at ≤25°C / ≤65% RH in sealed HDPE drums.

AMBICEL MCC 200 is the largest-particle, maximum-flow grade of Microcrystalline Cellulose produced by Maple Biotech, with a nominal particle size of 180 µm corresponding to the USP/NF PH-200 designation. The significantly larger particle diameter — approximately 3.6× that of MCC 101 — delivers the highest flowability of any standard MCC grade, making AMBICEL MCC 200 the first-choice excipient for formulations where powder flow is the primary challenge.

AMBICEL MCC 200 is specifically engineered for direct compression of high-dose APIs (where the API itself comprises ≥70% of the tablet weight) and for capsule-filling operations on modern high-speed dosators where any flow hesitation causes weight variation failures. The material's high bulk density (0.32–0.44 g/cm³) and excellent compressibility make it particularly suited to mini-tablets, orally disintegrating tablets (ODT), and paediatric formulations where tablet size must be minimised.

AMBICEL MCC 200 simultaneously meets USP/NF, EP, and IP pharmacopoeial specifications. Loss on drying ≤5.0%. Degree of polymerisation ≥200. Ash ≤0.1%. pH 5.0–7.5. Heavy metals ≤10 ppm (ICH Q3D). Shelf life 5 years. Available in 25 kg polyethylene-lined fibre drums. WHO-GMP batch documentation and full CoA supplied with every shipment. DMF LOA available on request.

AMBICEL MCC 301 is a specialist Microcrystalline Cellulose grade with a nominal particle size of 50 µm, specifically engineered for extrusion-spheronisation processes used in the manufacture of pellets and multiparticulate drug delivery systems. Unlike standard tablet-grade MCC, AMBICEL MCC 301 is optimised for high water-retention capacity and plasticity, which are the key properties that allow wet masses to extrude through die plates and then round into uniform spherical pellets on the spheroniser disc.

The extrusion-spheronisation process enabled by AMBICEL MCC 301 produces pellets with narrow size distribution (typically 0.5–1.5 mm), high sphericity, low friability, and excellent surface smoothness — properties essential for controlled-release coating (Eudragit®, HPMC, ethylcellulose). The resulting pellets fill capsules cleanly and release API in a reproducible, sustained manner. AMBICEL MCC 301 can be combined with APIs at loading ratios up to 80% w/w in optimal spheronisation conditions.

Grade meets USP/NF, EP (pellets preparation), and IP specifications for Microcrystalline Cellulose. LOD ≤5.0%. pH 5.0–7.5. Particle size distribution by laser diffraction: D90 ≤ 75 µm. ICH Q3D elemental impurity compliant. Shelf life: 5 years at ≤25°C in sealed original packaging. Full WHO-GMP documentation and CoA supplied.

AMBICEL MCC 302 is Maple Biotech's silicified grade of the spheronisation-specific MCC, combining the high water-retention plasticity of MCC 301 with the improved flow and moisture-barrier properties conferred by co-processed colloidal silicon dioxide (approximately 2% w/w). This dual-engineered material is designed for pharmaceutical manufacturers who require both extrusion-spheronisation performance and enhanced handling of hygroscopic APIs.

The silicon dioxide in AMBICEL MCC 302 forms an intimate surface coating that reduces interparticle cohesion in the dry powder state, improving sieve-through and die-plate passage during extrusion. Once wetted, the MCC matrix absorbs sufficient water to achieve the plastic, deformable consistency needed for spheronisation. The resulting pellets are denser and smoother than those from unsilicified MCC 301, which translates to improved coating efficiency and more uniform film thickness in subsequent Wurster or pan-coating operations.

AMBICEL MCC 302 is particularly recommended for moisture-sensitive APIs that degrade during the wet extrusion step when excessive water is used — the silicified matrix achieves acceptable spheronisation at lower water-to-MCC ratios. Complies with USP/NF Silicified MCC monograph and EP. LOD ≤5.0%. SiO₂ content 1.5–3.0%. ICH Q3D compliant. Shelf life: 5 years.

AMB-MYL MBC 581 is a precision-engineered MCC composite excipient from Maple Biotech's AMB-MYL range, formulated for superior direct compression performance. The 581 designation reflects a specific ratio of MCC to functional blend components, producing a material with significantly improved powder flowability, higher bulk density, and optimised compressibility compared to single-component MCC grades of equivalent particle size.

MBC 581 is manufactured through a controlled co-processing step that ensures intimate, homogeneous mixing of the MCC matrix with its blended components — unlike physical mixtures, the co-processed structure is resistant to segregation during transport, storage, and blend preparation. This segregation resistance is a critical attribute in large-scale tablet manufacturing where even slight particle separation causes tablet weight variation and content uniformity failures.

The compressibility profile of AMB-MYL MBC 581 enables higher tablet hardness at lower compression forces, reducing tooling wear and energy consumption on rotary tablet presses. It is particularly suited to mid-dose oral solid dosage forms where APIs constitute 30–60% of total tablet weight. Compatible with both hydrophilic and lipophilic APIs. Complies with USP/NF, EP, and IP for Microcrystalline Cellulose composite specifications. LOD ≤5.0%. pH 5.0–7.5. Shelf life: 5 years. Full WHO-GMP batch documentation and CoA supplied.

AMB-MYL MBC 591 is an advanced MCC composite excipient in Maple Biotech's AMB-MYL series, optimised for high-dose direct compression formulations where the API load exceeds 60% of the total tablet mass. The 591 grade's composition achieves the highest compressibility-to-bulk ratio in the AMB-MYL family, allowing formulators to produce acceptable tablets even when the excipient fraction is significantly constrained by API loading requirements.

In conventional MCC grades, the compressibility decreases as API loading increases because the API — often a poorly compressible crystalline substance — disrupts the MCC particle-particle bonding network. AMB-MYL MBC 591 mitigates this effect through a proprietary composite structure that maintains plastic deformation behaviour under compression even at high dilution, producing tablets with satisfactory hardness (≥80 N for 200 mg round tablets) even at 70% API loading.

This makes MBC 591 particularly valuable for generic pharmaceutical manufacturers working with high-dose BCS Class II and Class III APIs where direct compression is preferred over wet granulation for stability or cost reasons. Complies with USP/NF, EP, and IP. LOD ≤5.0%. pH 5.0–7.5. Residual heavy metals ≤10 ppm (ICH Q3D). Microbial limits per USP <61> / EP 2.6.12. Shelf life: 5 years at ≤25°C. Full WHO-GMP CoA supplied.

AMB-MYL MBC 611 is a MCC composite excipient from Maple Biotech, engineered to deliver a balanced combination of excellent flow, high compressibility, and rapid tablet disintegration within a single excipient. This trifunctional performance profile distinguishes MBC 611 from standard MCC grades, which typically require co-addition of a disintegrant to achieve acceptable tablet break-up times.

The disintegration-enhanced structure of MBC 611 incorporates disintegrant functionality within the composite matrix, allowing tablets compressed with this grade to disintegrate within 2–5 minutes in simulated gastric fluid without requiring a separate superdisintegrant addition. This simplifies the formulation (fewer excipients, fewer supplier qualifications, reduced Bill of Materials complexity) and reduces the risk of disintegrant–API incompatibilities.

MBC 611 is well-suited to immediate-release tablet formulations for general pharmaceuticals and nutraceuticals — particularly where rapid onset of action is a marketing claim or clinical requirement. The material flows freely on B-tooling and D-tooling presses and produces tablets with a smooth, printable surface. Compatible with film coating using HPMC-based systems. Complies with USP/NF, EP, IP. LOD ≤5.0%. pH 5.0–7.5. ICH Q3D compliant. Shelf life: 5 years. WHO-GMP CoA with every batch.

AMB-MYL MBC 811 is the premium-performance MCC composite in Maple Biotech's AMB-MYL series, designed for the most demanding direct compression applications where maximum tablet hardness, minimum capping tendency, and exceptional flow at high press speeds are simultaneously required. The 811 grade represents Maple Biotech's highest-performance composite formulation, combining optimised MCC crystallinity with synergistic blend components that extend the compaction pressure–hardness plateau, reducing sensitivity to compression force variation.

High-speed rotary tablet presses operating at 300,000+ tablets per hour impose extreme short dwell-time conditions — the punch head crosses the compression zone in milliseconds, leaving inadequate time for plastic deformation of poorly engineered materials. AMB-MYL MBC 811 is specifically characterised at high press speeds (≥60 rpm on simulated eccentric presses) to confirm hardness, friability, and disintegration remain within specification. This press-speed characterisation data is available to customers for ANDA/NDA submission as part of the supplier's technical dossier.

MBC 811 is ideal for pharmaceutical companies manufacturing large-volume generic tablets, OTC products, and nutraceutical tablets on high-output machinery. Complies with USP/NF, EP, IP. LOD ≤5.0%. pH 5.0–7.5. Full ICH Q3D elemental impurity profile. HALAL and KOSHER certified. Shelf life: 5 years at ≤25°C. WHO-GMP documentation and CoA supplied with every commercial batch.

AMBI-TCP is a co-processed excipient combining Microcrystalline Cellulose (MCC) and Tricalcium Phosphate (TCP, Ca₃(PO₄)₂, CAS 7758-87-4) produced by intimate co-spray drying. Tricalcium Phosphate is a calcium mineral salt with excellent compressibility, high bulk density, and a naturally alkaline pH — properties that complement the binding and disintegrating strengths of MCC while providing calcium content suitable for nutraceutical label claims.

The co-processing creates composite particles where TCP is uniformly distributed throughout the MCC matrix, not merely blended. This structural integration prevents segregation during tablet press feeding and ensures consistent tablet composition across every compression cycle. The combination delivers superior tablet hardness compared to either MCC or TCP alone at equivalent compression forces, alongside rapid disintegration and excellent chemical compatibility with slightly acid-sensitive APIs who benefit from the alkaline buffering of the TCP component.

AMBI-TCP is uniquely positioned for calcium-fortified nutraceutical tablets, antacid formulations, dietary supplement tablets, and veterinary pharmaceutical applications where calcium enrichment is a product attribute. The TCP component also acts as a glidant, reducing the colloidal silicon dioxide requirement. Complies with USP/NF, EP, and IP for both MCC and Tricalcium Phosphate constituent monographs. ICH Q3D compliant. HALAL/KOSHER certified. Shelf life: 5 years. Full WHO-GMP CoA supplied.

AMBI-CELACT is Maple Biotech's co-processed combination of Microcrystalline Cellulose and Lactose Monohydrate, produced by spray drying to create intimate composite particles. Lactose Monohydrate (CAS 5989-81-1) is the most widely used solid oral dosage form excipient globally, valued for its excellent compressibility, neutral taste, water solubility, and compatibility with the majority of APIs. When co-processed with MCC, lactose's brittle fracture mechanism combines with MCC's plastic deformation to produce tablets with outstanding hardness across a wide compression force range.

AMBI-CELACT outperforms physical binary blends of MCC and lactose in three key metrics: better flow (lower Carr index), higher tablet tensile strength at equivalent compression force, and faster disintegration due to the porous composite microstructure created during spray drying. The material is designed as a drop-in replacement for established commercial MCC–lactose combinations, offering equivalent or superior performance with the supply chain security and regulatory support of Maple Biotech's WHO-GMP manufacturing and US-DMF filings.

Note: AMBI-CELACT contains lactose and is contraindicated in lactose-intolerant patient populations. Not suitable for reducing-sugar-sensitive APIs (Maillard reaction risk). Complies with USP/NF, EP, IP for both components. LOD ≤5.0%. Residual solvents: ICH Q3C compliant. Heavy metals: ICH Q3D compliant. HALAL/KOSHER certified. Shelf life: 5 years at ≤25°C / ≤65% RH. Full WHO-GMP documentation and CoA supplied.

AMBI-GG is Maple Biotech's innovative co-processed excipient combining Microcrystalline Cellulose with Guar Gum (galactomannan polysaccharide, CAS 9000-30-0), produced by controlled co-processing to distribute guar gum uniformly within the MCC particle matrix. Guar gum is a natural hydrocolloid that swells rapidly and forms viscous gels in aqueous media, creating a diffusion barrier that controls drug release from the tablet matrix. When intimately co-processed with MCC, the composite achieves controlled drug release from a direct-compression tablet without the need for hot-melt extrusion or other complex manufacturing operations.

AMBI-GG provides formulation scientists with a convenient, single-excipient approach to sustained-release matrix tablet manufacture — eliminating the need for separate addition of guar gum powder, which is notoriously difficult to handle (dusty, prone to lumping, and inconsistent in flow) when added as a neat material. The co-processed structure ensures uniform guar gum distribution throughout each tablet, producing consistent release profiles across the batch and minimising the burst-release effect seen in poorly mixed matrix systems.

AMBI-GG is particularly relevant for BCS Class I APIs with short plasma half-lives where twice-daily or once-daily extended-release formulations provide clinical benefits. The guar gum component is of vegetable origin, HALAL and KOSHER certified. Complies with USP/NF, EP, IP for constituent excipients. ICH Q3D and Q3C compliant. Shelf life: 5 years at ≤25°C. Full WHO-GMP batch documentation and CoA supplied.

CEL-CA-DISSOL is Maple Biotech's brand of Croscarmellose Sodium (CCS), a cross-linked sodium carboxymethylcellulose produced by cross-linking sodium carboxymethylcellulose with citric acid, sodium carbonate, or by heat treatment to form an insoluble, fibrous network. CCS is classified as a superdisintegrant — it disintegrates tablets far more efficiently than traditional disintegrants like starch, at much lower use concentrations (2–5% vs. 5–20% for starch).

The disintegration mechanism of CCS involves two simultaneous processes: rapid water absorption by capillary wicking along the fibrous structure (hydrophilic cellulose backbone), followed by swelling of carboxymethyl groups — the cross-links prevent dissolution while allowing the fibre to expand, creating disruptive stress within the tablet matrix. Typical disintegration times of 2–5 minutes are achieved at 4% CCS concentration in compressed tablets. CEL-CA-DISSOL is effective both as an intragranular and extragranular disintegrant, with the optimal partition being 50:50 for many formulations.

US-FDA Drug Master File (DMF Type IV) filed for CEL-CA-DISSOL. Complies with USP/NF, EP, IP, JP. Sodium content ≤1.0%. pH 5.0–7.0 (1% suspension). Degree of substitution 0.60–0.85. ICH Q3D elemental impurity compliant. HALAL/KOSHER certified. Shelf life: 5 years at ≤25°C / ≤65% RH. Full WHO-GMP CoA with every batch.

CELTAB is Maple Biotech's Sodium Starch Glycolate (SSG) — a modified potato starch prepared by carboxymethylation and cross-linking. The carboxymethyl substituents dramatically increase water affinity, while the cross-links prevent complete dissolution, creating a polymer network that absorbs water and swells to approximately 300% of its original volume within 30 seconds of exposure to aqueous media. This rapid, high-magnitude swelling explosively disrupts tablet matrix integrity, making SSG one of the most effective superdisintegrants available for water-dispersible tablet technology.

CELTAB is manufactured in two types: Type A has low sodium content (<3.5% Na) and slightly acidic pH (3.0–5.0 in 3.3% w/v aqueous slurry), making it suitable for pH-sensitive formulations and sodium-restricted products. Type B has a sodium content of 2.8–5.0% and neutral-to-slightly alkaline pH (5.5–7.5), giving more robust buffering and is the general-purpose grade for the majority of solid oral dosage forms. Both types perform equivalently in terms of disintegration kinetics at 4–8% concentration.

US-FDA DMF Type IV filed for CELTAB. Complies with USP/NF, EP, IP, JP. Moisture content ≤10%. Apparent viscosity (1% w/v, 25°C) ≤200 mPa·s. ICH Q3D and Q3C compliant. HALAL/KOSHER certified. Shelf life: 5 years at ≤25°C / ≤65% RH. WHO-GMP CoA supplied.

MYLCEL is Maple Biotech's brand of Low-Substituted Hydroxypropyl Cellulose (L-HPC) — a cellulose ether with a low degree of hydroxypropyl substitution (5–16% HP content, corresponding to MS 0.1–0.4) that renders the polymer water-insoluble yet highly water-swellable. This unusual combination — insoluble but strongly swelling — makes L-HPC a uniquely dual-functional excipient: a binder in wet granulation and a disintegrant in the finished tablet.

During wet granulation, MYLCEL dissolves partially in the granulation liquid and, on drying, forms solid bridges between API and filler particles — providing granule strength and reducing friability. During tablet dissolution in the GI tract, water penetrates the tablet matrix, the L-HPC particles swell extensively (2–5× volume), and the resulting swelling pressure fractures the tablet from within. This single-excipient binder-disintegrant functionality simplifies formulation by reducing the number of excipients required and eliminating the potential incompatibility between binder and disintegrant phases.

MYLCEL is particularly favoured in Japanese pharmaceutical manufacturing, where L-HPC was developed and has the longest regulatory track record. It is also widely used in European and US generic formulations. Complies with USP/NF, EP, IP, JP. Water content ≤5.0%. HP content 5.0–16.0% (dry basis). Loss on ignition ≤0.5%. ICH Q3D compliant. HALAL/KOSHER certified. Shelf life: 5 years. Full WHO-GMP documentation and CoA supplied.

CRODIS XL-10 A is Maple Biotech's fine-particle grade of Crospovidone — insoluble, cross-linked polyvinylpyrrolidone produced by polymerisation of N-vinyl-2-pyrrolidone in the presence of a cross-linking agent. Unlike CCS and SSG, crospovidone does not swell significantly on water contact; instead, it disintegrates tablets primarily by rapid wicking of water via capillary action through its porous, sponge-like particle structure. This capillary-action mechanism generates sufficient hydraulic pressure within the tablet to overcome the binding forces and break apart the matrix within 1–3 minutes.

The key advantage of crospovidone over cellulose and starch-based disintegrants is its minimal swelling — this makes it the disintegrant of choice for moisture-sensitive APIs and for formulations where tablet dimensional stability (no swelling in storage) is a regulatory or packaging requirement. CRODIS XL-10 A is the fine grade (D90 ≤ 400 µm) suitable for direct compression blends and for intragranular addition in wet granulation where particle fineness improves distribution within the granule.

CRODIS XL-10 A is insoluble in water, organic solvents, and dilute acids/alkalis. pH of 1% suspension: 5.0–8.0. LOD ≤5.0%. Peroxide content ≤400 ppm. Complies with USP/NF Type A, EP, IP. ICH Q3D compliant. HALAL/KOSHER certified. Shelf life: 5 years at ≤25°C. WHO-GMP CoA supplied with every batch.

CRODIS XL-10 B is Maple Biotech's coarser-particle grade of Crospovidone (Type B per USP/NF), with a particle size D90 ≤ 800 µm. The larger particle size of Type B compared to Type A (XL-10 A) results in lower surface area per unit mass and modestly reduced water absorption rate — however, it delivers superior tablet disintegration when used as an extragranular disintegrant, because the larger particles create a more open, discontinuous network within the tablet that channels water more effectively to the interior.

CRODIS XL-10 B is the preferred grade for extragranular addition in wet-granulated formulations, where it is blended with dried granules immediately before compression. The coarser particles do not penetrate granule pores and remain at intergranular positions, maximally exploiting their wicking mechanism for rapid water penetration into the whole tablet mass. The coarser grade also flows better than Type A, simplifying blending in planetary or tumble mixers without bridging or rat-holing in hoppers.

Where both intragranular and extragranular disintegrant addition is desired, a 50:50 split using CRODIS XL-10 A (intragranular) and CRODIS XL-10 B (extragranular) has been shown to produce faster overall disintegration than using either grade alone at the same total concentration. Complies with USP/NF Type B, EP, IP. LOD ≤5.0%. Peroxide ≤400 ppm. ICH Q3D compliant. Shelf life: 5 years. WHO-GMP CoA supplied.

POVIMINE K30 is Maple Biotech's Povidone with K-value 27–32 (mean molecular weight approximately 40,000 Daltons) — the single most commonly used pharmaceutical binder grade of PVP worldwide. Chemically, Povidone is a homopolymer of N-vinyl-2-pyrrolidone (1-ethenyl-2-pyrrolidinone) produced by free-radical polymerisation in isopropanol; the K-value describes the relative viscosity of a dilute aqueous solution and is directly related to average molecular weight and binding performance.

In wet granulation, POVIMINE K30 is dissolved in water, ethanol, isopropanol, or other solvents to form a binder solution (typically 5–15% w/v) that is sprayed or poured onto the API-filler blend in a high-shear or planetary mixer. On drying, PVP deposits as a strong, flexible film at particle contact points, forming granules of controlled hardness and porosity. The resulting granules have excellent flow and compress to tablets with high tensile strength and rapid disintegration (PVP does not form a hydrophobic barrier). POVIMINE K30 is also used as a dry binder in direct compression at 0.5–5% concentration.

POVIMINE K30 is additionally used as a solubility enhancer for BCS Class II drugs via hot-melt extrusion (HME) or spray drying, creating amorphous solid dispersions (ASDs) that dramatically increase aqueous solubility. Complies with USP/NF, EP, IP, JP. Vinylpyrrolidone monomer ≤10 ppm. Hydrazine ≤1 ppm. ICH Q3C Class 3 solvents compliant. Heavy metals ICH Q3D. HALAL/KOSHER. Shelf life: 5 years. WHO-GMP CoA supplied.

POVIMINE K90 is Maple Biotech's high-molecular-weight Povidone grade with K-value 85–95 (mean molecular weight approximately 1,000,000 Daltons — 25× higher than K30). The dramatically higher molecular weight of K90 results in stronger inter-particle binding forces, higher solution viscosity, and greater film-forming strength compared to K30. POVIMINE K90 is the binder of choice for formulations requiring maximum granule hardness, sustained-release matrix formation, or extended film integrity.

In wet granulation, POVIMINE K90 is used as a more concentrated binder (typically 2–5% w/w of granulation blend) because its higher molecular weight achieves equivalent or superior binding at lower concentrations than K30. In modified-release tablet matrix applications, higher concentrations of K90 (up to 15%) can act as a hydrophilic matrix former — as the tablet hydrates, PVP K90 forms a viscous gel layer that controls drug diffusion out of the eroding matrix, enabling zero-order or Higuchi-type release profiles.

POVIMINE K90 is also used in ophthalmic preparations as a viscosity modifier and lubricant in artificial tear solutions, and in topical preparations as a film-former and binder. Complies with USP/NF, EP, IP, JP. K-value 85.0–95.0. Vinylpyrrolidone monomer ≤10 ppm. Hydrazine ≤1 ppm. ICH Q3D heavy metals compliant. LOD ≤5.0%. HALAL/KOSHER certified. Shelf life: 5 years at ≤25°C / ≤65% RH. Full WHO-GMP documentation and CoA supplied.

STEARION is Maple Biotech's pharmaceutical-grade Magnesium Stearate — the magnesium salt of stearic acid (and a mixture of magnesium palmitate and magnesium stearate as found naturally in vegetable fat sources). It is the most universally used lubricant in tablet and capsule manufacturing globally, present in the majority of all solid oral dosage forms at concentrations of 0.25–2.0% w/w. STEARION is manufactured from vegetable-source fatty acids, meeting HALAL and KOSHER requirements, and is available in pharmaceutical-grade quality with a Mg content of 4.0–5.0%.

The lubrication mechanism of magnesium stearate is a combination of a thin hydrophobic film deposited on granule and punch-face surfaces during blending, which reduces metal-to-particle and particle-to-particle friction. STEARION must be blended carefully: over-blending (more than 2–5 minutes in most cases) causes excessive coating of hydrophilic granule surfaces, significantly retarding tablet disintegration and drug dissolution — a phenomenon well-documented in the literature and a critical process parameter in GMP validation. A blend time of 2–3 minutes at 15–20 rpm is recommended for most Turbula/V-blender operations.

STEARION is chemically inert with almost all APIs. Key exceptions: avoid with strongly acidic APIs (low pH oxidises the stearate), and use with caution with acetylsalicylic acid. Complies with USP/NF, EP, IP, JP. Acid value ≤6.0. LOD ≤6.0%. Mg content 4.0–5.0% (anhydrous basis). Heavy metals ICH Q3D. Nickel ≤2 ppm. HALAL/KOSHER certified. Shelf life: 5 years. WHO-GMP CoA supplied.

STEAREX is Maple Biotech's pharmaceutical-grade Calcium Stearate — the calcium salt of stearic acid (CAS 1592-23-0, Ca(C₁₇H₃₅COO)₂). While Magnesium Stearate (STEARION) is the dominant lubricant in solid dosage forms, Calcium Stearate offers several advantages in specific formulation scenarios: it is less hygroscopic, produces slightly harder tablets at equivalent use concentrations, and causes less retardation of drug dissolution because it is comparatively less hydrophobic than magnesium stearate.

STEAREX is preferred over STEARION in formulations where dissolution retardation from lubricant coating is a significant concern — for example, highly dose-dependent APIs with narrow therapeutic windows where small changes in dissolution rate could affect clinical performance. Calcium stearate is also the preferred lubricant in chewable tablets and effervescent tablets where magnesium stearate's stronger hydrophobicity would impede the rapid dissolution and effervescence required.

STEAREX is manufactured from vegetable-source fatty acids (HALAL/KOSHER certified) by reaction of calcium hydroxide with stearic acid. The vegetable origin is confirmed by fatty acid profile by GC/MS, distinguishing it from bovine or mixed animal-source calcium stearate. Complies with USP/NF, EP, IP, JP. Calcium content 6.4–7.4%. Acid value ≤10.0. LOD ≤4.0%. Heavy metals ICH Q3D. Shelf life: 5 years at ≤25°C. Full WHO-GMP documentation and CoA provided.

COSILIFLOXA is Maple Biotech's Colloidal Silicon Dioxide (fumed silica) — an amorphous, sub-microscopic form of silicon dioxide (SiO₂) produced by flame hydrolysis of silicon tetrachloride at very high temperatures. The resulting material consists of primary particles approximately 5–50 nm in diameter that aggregate into three-dimensional, porous networks with an extremely high specific surface area of 175–225 m²/g (BET). This vast surface area is responsible for COSILIFLOXA's exceptional glidant and adsorptive properties at very low use concentrations.

As a glidant, COSILIFLOXA functions by coating the surfaces of larger powder particles, disrupting inter-particle van der Waals forces and reducing cohesion — the dominant cause of poor powder flow in pharmaceutical blends. At concentrations as low as 0.1–0.5% w/w, COSILIFLOXA can reduce the Carr index of problematic blends from >35 (very poor flow) to <15 (excellent flow). This improvement in flow translates directly to reduced tablet weight variation and lower rejection rates in commercial tablet manufacture.

COSILIFLOXA is also used as an adsorbent for liquid APIs (e.g., oils, liquid vitamins) — the high surface area absorbs liquids to form free-flowing powders suitable for tableting or encapsulation. In suspensions and gels, it acts as a thickener and suspension stabiliser. Complies with USP/NF, EP, IP, JP. SiO₂ content (ignited) ≥99.0%. LOD ≤2.5%. pH (4% dispersion) 3.5–4.5. Heavy metals ICH Q3D. Shelf life: 5 years. WHO-GMP CoA supplied.

MABITAB 1500 is Maple Biotech's Partially Pregelatinized Maize Starch — a physically modified corn starch where approximately 5–20% of the native starch granules have been gelatinised by heating in the presence of water, then dried and milled. This controlled partial gelatinisation creates a bimodal material: intact native starch granules (which retain the disintegration properties of native starch) co-exist with gelatinised amorphous starch regions (which provide binding without added water).

This bimodal structure gives MABITAB 1500 its unique dual functionality as both a binder and a disintegrant in direct compression — properties that native starch lacks. The gelatinised fraction binds granule components during compression; the native starch fraction swells in the GI tract water, promoting rapid tablet disintegration. This eliminates the need for separate binder and disintegrant additions in simple formulations, reducing total excipient count and processing time.

MABITAB 1500 is particularly widely used in over-the-counter (OTC) tablet formulations, herbal and traditional medicine tablets, and nutraceutical tablets where clean-label excipient lists are preferred. It is GMO-status documented, of plant (maize) origin, HALAL and KOSHER certified. Complies with USP/NF, EP, IP. LOD ≤14.0%. pH 4.5–7.0 (20% suspension). Acid value and oxidising substances within pharmacopoeial limits. ICH Q3D compliant. Shelf life: 5 years at ≤25°C / ≤65% RH. WHO-GMP CoA supplied.

MABITAB 3000 is Maple Biotech's Fully Pregelatinized Starch — produced by complete gelatinisation of maize or potato starch in aqueous suspension under heat and shear, followed by drum drying or spray drying. The fully gelatinised product consists entirely of collapsed, amorphous starch particles with no residual crystalline granule structure. This complete structural transformation converts starch from a poor direct compression excipient (native starch has low compressibility, poor flow, and no inherent flow properties) into a functional direct compression binder-filler.

MABITAB 3000's amorphous structure is responsible for its excellent compressibility — amorphous polymers deform plastically under compression forces, forming strong tablet matrices without requiring high compaction pressures. Additionally, pregelatinized starch exhibits mild self-lubricating properties due to surface amylose alignment, potentially reducing magnesium stearate requirements. It is tasteless, odourless, and provides a pleasant mouthfeel in chewable and rapidly disintegrating tablets.

MABITAB 3000 is among the most versatile tableting excipients available — functioning simultaneously as filler, binder, and mild disintegrant at concentrations of 5–30%. It is widely used in generics, OTC products, and nutraceutical tablets globally. GMO-status documented, HALAL/KOSHER certified. Complies with USP/NF (Pregelatinized Starch), EP (Pregelatinised Starch), IP. LOD ≤14%. pH 4.5–7.0. Sulphited starch absent. ICH Q3D compliant. Shelf life: 5 years. WHO-GMP CoA supplied.

AMYLATO is Maple Biotech's pharmaceutical-grade Potato Starch (Solanum tuberosum), produced from fresh potatoes by aqueous extraction, purification, and controlled drying. Potato starch has the largest granule size of the commercially important native starches (15–100 µm, compared to 2–30 µm for maize starch) and the highest proportion of amylopectin (~79%). These structural characteristics give potato starch its uniquely high water-absorption capacity and powerful swelling disintegration action in tablets — potato starch absorbs approximately 2–3× more water per gram than maize starch, generating a larger disintegrating force.

AMYLATO serves three functional roles in pharmaceutical formulations. As a disintegrant (5–15%), it provides reliable tablet break-up through starch granule swelling when in contact with gastric fluid. As a binder in wet granulation (2–10% starch paste), freshly gelatinised potato starch solution creates excellent granule binding strength. As a diluent/filler (up to 80%), it provides bulk in high-dosage tablets and capsules where the API dose is small. Potato starch has a very low protein content compared to maize starch, making it preferable for allergen-sensitive formulations.

AMYLATO meets USP/NF, EP, IP, and JP monograph specifications for Potato Starch simultaneously. LOD ≤21%. pH 5.0–8.0. Sulphur dioxide ≤50 ppm. Oxidising substances: compliant. Heavy metals: ICH Q3D. HALAL/KOSHER certified. Shelf life: 5 years at ≤25°C / ≤65% RH in sealed original packaging. WHO-GMP batch documentation and CoA supplied.

AMYLAIZE is Maple Biotech's pharmaceutical-grade Maize Starch (Corn Starch, Zea mays), produced from corn kernels by wet milling, aqueous purification, and controlled drying. Maize starch is the most globally abundant pharmaceutical starch excipient and appears in the majority of solid oral dosage form pharmacopoeial formulas. The small granule size (2–30 µm), relatively high amylose content (~27%), and consistent supply position maize starch as the standard reference starch in pharmaceutical formulation.

AMYLAIZE performs the same three functional roles as AMYLATO (potato starch) — disintegrant, wet granulation binder (as paste), and filler — but with distinct performance characteristics. Its smaller granule size provides more uniform distribution in tablet blends and a smoother tablet surface compared to potato starch. The lower water absorption relative to potato starch results in faster but less powerful disintegration, generally achieving disintegration times of 5–15 minutes at 5–10% concentration in standard tablet formulations.

AMYLAIZE is used in virtually every therapeutic category — analgesics, antibiotics, cardiovascular, antidiabetics, vitamins and dietary supplements. It is one of the most extensively characterised pharmaceutical excipients with decades of human safety data. GMO-status documented (non-GMO on request). HALAL/KOSHER certified. Complies with USP/NF, EP, IP, JP. LOD ≤15%. pH 4.5–7.0. Sulphur dioxide ≤50 ppm. ICH Q3D compliant. Shelf life: 5 years. WHO-GMP CoA supplied.

LACTISOL is Maple Biotech's pharmaceutical-grade Lactose Monohydrate (α-lactose monohydrate, C₁₂H₂₂O₁₁·H₂O) — the most widely used solid dosage form filler globally, derived from whey (bovine milk) by crystallisation from concentrated permeate. Lactose monohydrate combines excellent compressibility (brittle fracture mechanism complementing MCC's plastic deformation), chemical stability, pleasant sweetness, and regulatory familiarity spanning decades of use in both innovator and generic drug products across all therapeutic areas.

LACTISOL is supplied in multiple crystal size grades suited to different applications: fine crystalline grades (D50 ~30–60 µm) for wet granulation and as a capsule-fill diluent; spray-dried grades (D50 ~100–150 µm) with rounded, porous particles optimised for direct compression with superior flow and compressibility; and inhalation grades (D50 ~70–80 µm, endotoxin tested) for dry powder inhalers (DPI) where lactose acts as a carrier for micronised API particles. Maple Biotech will confirm available grade specifications upon enquiry.

Important contraindications: LACTISOL contains lactose (a reducing sugar) and should not be used with amine-containing APIs susceptible to Maillard browning. Not suitable for patients with galactosaemia or severe lactose intolerance (though the pharmacopoeial limit is <300 mg/dose for most populations). Complies with USP/NF, EP, IP, JP. LOD ≤0.5%. Specific rotation +54.4° to +55.9°. Sulphated ash ≤0.1%. Heavy metals ICH Q3D. Shelf life: 5 years. WHO-GMP CoA supplied.

CELVIA is Maple Biotech's Powdered Cellulose — a purified, mechanically disintegrated alpha-cellulose prepared by milling wood pulp to produce fine particles of varying size distribution, distinguished from Microcrystalline Cellulose (MCC) by the absence of the acid hydrolysis step that removes amorphous cellulose from MCC. As a result, CELVIA retains both crystalline and amorphous cellulose regions, giving it slightly different mechanical properties — generally lower compressibility than MCC but similar chemical inertness and moisture absorption.

CELVIA is primarily used as a filler and diluent in tablets and capsules, a tableting aid in dry granulation (roller compaction), and an anti-caking agent in powdered products. In fibre-fortified pharmaceutical products and dietary supplements, CELVIA can contribute a dietary fibre label claim. Its fibrous nature also contributes to tablet disintegration through a wicking mechanism similar to CCS, though less potent than superdisintegrants.

CELVIA is available in fine (D50 ~50 µm), medium (D50 ~100 µm), and coarse (D50 ~200 µm) grades to suit different tableting and capsule-fill requirements. The fine grade is suitable for direct compression with good tablet surface smoothness; coarser grades are preferred in roller compaction operations where material bridging is a concern. Complies with USP/NF, EP, IP, JP. LOD ≤7.0%. pH 5.0–7.5. Water soluble substances ≤1.5%. Heavy metals ICH Q3D. HALAL/KOSHER certified. Shelf life: 5 years. WHO-GMP CoA supplied.

CARBOGENIX is Maple Biotech's Sodium Carboxymethylcellulose (Sodium CMC) — produced by reacting alkali-swollen cellulose with sodium monochloroacetate, introducing carboxymethyl (−CH₂COONa) groups along the cellulose backbone. The degree of substitution (DS) typically ranges from 0.7–1.2 carboxymethyl groups per anhydroglucose unit, making the polymer anionic, water-soluble, and highly hydrophilic. CARBOGENIX is supplied in multiple viscosity grades (low: 25–50 mPa·s; medium: 400–800 mPa·s; high: 2000–4000 mPa·s, measured as 1% w/v solution at 25°C).

In oral solid dosage forms, low-viscosity CARBOGENIX grades function as binders and disintegrants in wet granulation — the sodium CMC solution binds granules and, after drying, swells on contact with GI fluid to promote disintegration. In topical formulations, medium to high-viscosity grades produce gels with pseudoplastic rheology (shear thinning), ideal for creams, lotions, toothpaste, and ophthalmic lubricating drops. In oral liquid formulations, CARBOGENIX acts as a suspending agent, preventing API particle sedimentation and providing pour-consistency.

CARBOGENIX is compatible with most APIs over a pH range of 4–11. It is sensitive to divalent cation precipitation (Ca²⁺, Mg²⁺) and strong mineral acids. Complies with USP/NF (Carmellose Sodium), EP, IP, JP. DS 0.70–1.20. pH 6.5–8.5 (1% solution). Sodium content 6.5–8.5%. ICH Q3D compliant. HALAL/KOSHER certified. Shelf life: 5 years at ≤25°C / ≤65% RH. WHO-GMP documentation and CoA supplied.

CEL-CA-CAL is Maple Biotech's Calcium Carboxymethylcellulose (Carmellose Calcium) — the calcium salt form of CMC, produced by cation exchange from sodium CMC. Unlike sodium CMC (CARBOGENIX), which is freely water-soluble, calcium CMC is water-insoluble — the divalent calcium ions bridge neighbouring carboxymethyl groups, forming an insoluble crosslinked-like structure. This insolubility is precisely what makes calcium CMC a highly effective tablet disintegrant with significant swelling capacity.

CEL-CA-CAL functions primarily as a disintegrant in tablets and capsules at use concentrations of 2–10%. On contact with water in the GI tract, calcium ions exchange with sodium ions in the fluid, disrupting the calcium bridges and allowing the CMC polymer chains to hydrate and swell extensively — disintegrating the tablet from within. This mechanism is particularly effective in the near-neutral pH of the small intestine where most drug absorption occurs, making calcium CMC well-suited for enteric formulations and formulations requiring reliable small-intestinal disintegration.

CEL-CA-CAL is available in pharmaceutical grade in multiple particle size fractions for fine-tuning of disintegration kinetics. It is compatible with cationic APIs more favourably than sodium CMC. Complies with USP/NF (Carmellose Calcium), EP, IP. Calcium content 3.5–4.5%. pH (1% w/v suspension) 4.5–6.5. DS 0.60–0.85. Water soluble fraction ≤10.0%. ICH Q3D compliant. HALAL/KOSHER certified. Shelf life: 5 years. WHO-GMP CoA supplied.

AMBICELOX is Maple Biotech's Oxidised Cellulose — produced by controlled oxidation of cellulose using nitrogen dioxide (NO₂) or periodate reagents, converting primary hydroxyl groups on C-6 of the anhydroglucose units to carboxyl groups. The resulting material, with carboxyl content typically between 16–24%, is an acidic, water-insoluble polymer that dissolves in alkaline solutions (pH >7.0) and is completely biodegradable and bioabsorbable in vivo through chemical hydrolysis and enzymatic action.

The unique combination of bioabsorbability, haemostatic activity (promoting platelet aggregation at the wound site), and controlled dissolution at alkaline pH gives AMBICELOX a distinctive niche in pharmaceutical applications. As a haemostatic excipient in surgical preparations, oxidised cellulose controls bleeding from oozing wounds where other haemostatic measures are impractical. In pharmaceutical formulations, it serves as a pH-triggered modified-release matrix material — the polymer remains intact in stomach acid but rapidly dissolves in the alkaline small intestine, enabling targeted colon or intestinal drug delivery.

AMBICELOX is also used in wound dressing devices and bioabsorbable implantable pharmaceutical applications. It is fully degraded in tissues within 7–14 days without systemic toxicity. Complies with USP/NF, EP, IP. Carboxyl content 16–24% (expressed as uronic acid content). Loss on drying ≤10.0%. pH (1% in 0.9% NaCl) 2.0–4.0. Sterile grades available upon request. ICH Q3D compliant. Shelf life: 5 years. WHO-GMP CoA supplied with each batch.

MALTOSURE is Maple Biotech's pharmaceutical-grade Maltodextrin — a water-soluble polysaccharide produced by partial enzymatic or acid hydrolysis of starch (maize or potato), characterised by a Dextrose Equivalent (DE) value of less than 20. The DE value reflects the degree of hydrolysis: DE 1 is essentially unhydrolysed starch; DE 20 is a polymer of approximately 5 glucose units average. Lower DE values result in higher molecular weight, lower sweetness, and greater film-forming capacity — properties exploited in pharmaceutical applications.

MALTOSURE serves four primary pharmaceutical functions. As a spray-drying carrier, it encapsulates lipid-based drug delivery systems, essential oils, vitamins, and unstable APIs — the dissolved maltodextrin matrix encapsulates the active material during atomisation and drying, forming a protective glassy matrix that prevents oxidation and volatilisation. As a lyophilisation bulking agent, it provides structure to freeze-dried products (lyophilised injectables, biologics), preventing cake collapse. As a tablet filler for water-soluble formulations requiring rapid dissolution, it dissolves completely on contact with oral fluids. As a taste masking agent, the starchy texture of maltodextrin masks bitter API flavours in chewable and orally disintegrating tablet formulations.

MALTOSURE is of plant (maize) origin, GMO-status documented, HALAL/KOSHER certified. Complies with USP/NF, EP, IP. Dextrose Equivalent <20. LOD ≤6.0%. pH 4.0–7.0 (10% w/v solution). Sulphated ash ≤0.5%. Microbial limits per USP <61>/<62>. Heavy metals ICH Q3D. Shelf life: 5 years at ≤25°C / ≤65% RH. WHO-GMP batch documentation and CoA provided.

MAPECTIN is Maple Biotech's pharmaceutical-grade Pectin — a purified heteropolysaccharide extracted from citrus peel (Citrus sinensis or Citrus limon) or apple pomace by controlled aqueous extraction at slightly acidic pH. The primary structural unit is galacturonic acid, organised in long chains with varying degrees of methyl esterification. High-methoxyl pectins (HM, degree of methoxylation >50%) gel in acidic conditions (<pH 3.5) in the presence of high sugar concentrations. Low-methoxyl pectins (LM, <50% methoxylation) gel across a wider pH range in the presence of calcium ions, making them broadly applicable in pharmaceutical systems.

MAPECTIN is used in pharmaceutical formulations across several application domains. As a colon-targeted drug delivery matrix, pectin resists hydrolysis in the stomach and small intestine (where human pectinases are absent) but is fermented by colonic bacteria (Bacteroides, Bifidobacterium, Lactobacillus species), releasing the encapsulated API specifically in the colon — ideal for inflammatory bowel disease drugs, colon cancer agents, and local anti-infectives. As a controlled-release hydrogel matrix, calcium-crosslinked LM pectin beads produced by ionotropic gelation provide sustained release over 8–24 hours. As an oral rehydration formulation aid, soluble pectin reduces the osmolarity of electrolyte solutions and improves consistency for paediatric use.

MAPECTIN is of vegetable origin (citrus/apple), free from animal-derived ingredients, HALAL and KOSHER certified. Complies with USP/NF, EP, IP. Galacturonic acid content (anhydrous) ≥74.0%. Methoxyl content 6.0–9.0% (for standard grade). LOD ≤12.0%. Heavy metals ICH Q3D. Microbiological quality per USP <61> / EP 2.6.12. Shelf life: 5 years at ≤25°C. Full WHO-GMP documentation and CoA supplied with every batch.